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Abstract:  
Background: Consensus guidelines are not available for the use of immunoglobulin replacement 
therapy (IGRT) in patients developing iatrogenic secondary antibody deficiency following B-cell 
targeted therapy (BCTT) in autoimmune rheumatic disease. 
Objectives: To evaluate the role of IGRT to manage hypogammaglobulinemia following BCTT in 
autoimmune rheumatic disease (AIRD). 
Methods: Using an agreed search string we performed a systematic literature search on Medline with 
Pubmed as vendor. We limited the search to English language papers with abstracts published over 
the last 10 years. Abstracts were screened for original data regarding hypogammaglobulinemia 
following BCTT and the use of IGRT for hypogammaglobulinemia following BCTT. We also searched 
current recommendations from national/international organisations including British Society for 
Rheumatology, UK Department of Health, American College of Rheumatology, and American Academy 
of Asthma, Allergy and Immunology. 
Results: 222 abstracts were identified. Eight papers had original relevant data that met our search 
criteria. These studies were largely retrospective cohort studies with small patient numbers receiving 
IGRT. The literature highlights the induction of a sustained antibody deficiency, risk factors for 
hypogammaglobulinemia after BCTT including low baseline serum IgG levels, how to monitor patients 
for the development of hypogammaglobulinemia and the limited evidence available on intervention 
thresholds for commencing IGRT.   
Conclusion: The benefit of BCTT needs to be balanced against the risk of inducing a sustained 
secondary antibody deficiency. Consensus guidelines would be useful to enable appropriate 
assessment prior to and following BCTT in preventing and diagnosing hypogammaglobulinemia. 
Definitions for symptomatic hypogammaglobulinemia, intervention thresholds and treatment targets 
for IGRT, and its cost-effectiveness are required.  
Keywords:  rituximab, anti-CD20, vasculitis, ANCA, hypogammaglobulinemia, infection 
Abbreviations: AIRD = autoimmune rheumatic disease, AAV = ANCA-associated vasculitis, BCTT= B-
cell targeted therapy, DoH = Department of Health, EULAR = European League Against Rheumatism, 
GPA = granulomatosis with polyangiitis, IGRT= immunoglobulin replacement therapy, RA = 
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Rheumatoid arthritis, SLR = systematic literature review, SPUR = serious, persistent, unusual or 
recurrent, UK= United Kingdom 
 
Take home messages 
1. Immunoglobulin replacement therapy for secondary hypogammaglobulinemia is increasing, 
due to B-cell targeted therapy use in autoimmune rheumatic diseases. There are no consensus 
guidelines available for immunoglobulin replacement in this population.   
2. This review highlights the currently available literature, including risk factors for 
hypogammaglobulinemia after B-cell targeted therapy, how to monitor for development of 
hypogammaglobulinemia, and intervention thresholds for commencing immunoglobulin 
replacement. 
3. The need for consensus guidelines is highlighted for the appropriate assessment to prevent 
and to diagnose hypogammaglobulinemia early, and to optimize the management of 
immunoglobulin replacement therapy in this group. 
 
1. Introduction 
Primary immunodeficiency (PID) is due to inherited or sporadic genetic mutation(s), and may have 
unknown environmental cofactors, but no other known cause [1,2]. Secondary immunodeficiency 
(SID) may occur consequent to disease or effects of drugs or therapies [3,4]. Immunoglobulin 
replacement therapy (IGRT) for drug-related secondary hypogammaglobulinemia is increasing, due to 
the use of B-cell targeted therapies (BCTT) for management of autoimmune rheumatic diseases (AIRD) 
and B-cell lymphoproliferative disease. Hypogammaglobulinemia is characterised by reduction in 
circulating immunoglobulins (Ig) and can predispose to severe and recurrent infections [6]. Underlying 
immune dysfunction and prolonged immunosuppressive drug use result in patients being at greater 
risk of infection, a major cause of morbidity and mortality in this population [3].  
BCTT are effective treatments, but concerns remain over the long-term effects on humoral immunity 
with potential development of hypogammaglobulinemia and increased risk of infection [7, 8, 9, 10].    
CD20+ B-cells are depleted by rituximab on average for 6–12 months, though there is substantial 
variability with longer periods of depletion observed in ANCA-associated vasculitis (AAV) [7]. Mature 
plasma cells do not express CD20 and are the source of 95% of circulating immunoglobulin G (IgG) [7]. 
Most patients do not have residual immune dysfunction as B-cell numbers typically recover, and early 
reports suggested no major effect on serum immunoglobulins [11, 12]. Hypogammaglobulinemia and 
associated infection risks are thought to be secondary to prolonged depletion of plasma cell 
precursors, which may contribute to reduced replenishment of mature plasma cells [7, 13]. There is 
limited data on the frequency of IGRT for rituximab-associated hypogammaglobulinemia, ranging 
from 6.6% in lymphoma to 14 -21% in systemic vasculitis [14]. Reports also are found in immune 
thrombocytopenia treated with BCTT [15]. 
Currently consensus guidelines are not available for the use of IGRT in patients developing iatrogenic 
secondary antibody deficiency following either BCTT or other immunosuppressive therapies in AIRD. 
This review evaluates the current literature in adults to aid diagnostic and therapeutic decision making 
for clinicians. We have not addressed the paediatric literature; however, the information may be of 
interest to paediatricians managing AIRD patients. 
2. Methods 
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This systematic literature review (SLR) was performed in accordance with the Scottish Intercollegiate 
Guidelines Network (SIGN) methodology [16].  The search topics included in the SLR were identified 
through a Delphi process. We used the following search string on 1st September 2018- "(Immunologic 
Deficiency Syndromes"[Mesh] NOT "HIV Infections"[Mesh]) AND (("Antibodies, Monoclonal"[Mesh] 
OR "Abatacept"[Mesh] OR "TACI receptor-IgG Fc fragment fusion protein"[Supplementary Concept]) 
OR ("Immunoglobulin G/administration and dosage"[Mesh] AND "Immunoglobulin G/therapeutic 
use"[Mesh])) NOT ("case reports"[pt] OR "Review"[pt])”. The results were limited by using the filters 
‘abstracts’ ‘English language’ and ‘published in last 10 years’. Of the 222 papers identified, data was 
harvested from 8 original articles. SIGN checklist screening of each article was performed prior to 
inclusion.  Data from the current publications produced by national/international organisations were 
also reviewed, and the reference lists hand searched. These included: British Society for 
Rheumatology, UK Department of Health, European League Against Rheumatism, European Society 
for Immunodeficiencies, American College of Rheumatology, and American Academy of Allergy, 
Asthma, & Immunology, yielding a further 11 publications (Figure 1).  
 
Figure 1: Selection of studies flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Results 
3.1 Distinction between purely numerical hypogammaglobulinemia and symptomatic 
hypogammaglobulinemia  
The current literature provides no definition to differentiate purely numerical from symptomatic 
hypogammaglobulinemia. Studies included in this review defined hypogammaglobulinemia at varying 
levels of <4 to <7.5 g/L [Table 1]. The lower limit of the normal range may vary depending on age, 
6 
 
population, and the particular assay [8]. Specific cut-off IgG levels necessitating IGRT are unclear. 
Many patients are asymptomatic with low IgG levels and IgG levels may recover following BCTT.  In 
one series of 243 patients with systemic autoimmune disease who received rituximab, 26% developed 
moderate (defined as 3-4.9 g/L) or severe (< 3 g/L) hypogammaglobulinemia. This was often transient 
and improved spontaneously in approximately 50% of cases [8]. This study reported IgG levels in 
patients who develop hypogammaglobulinemia within 6 months of the first rituximab dose may 
recover spontaneously without use of IGRT [8]. Hypogammaglobulinemia at the initiation of rituximab 
treatment is suspected to be multifactorial, such as due to active disease or other treatments, and 
may be transient. However later onset hypogammaglobulinemia after rituximab is considered more 
likely to be sustained, and related to prolonged B-cell depletion [8]. As by far the dominant BCTT agent 
in clinical use is rituximab, the available data are concentrated on this medication, with no data 
available for other depleting BCTT such as ocrelizumab in AIRD. 
In an 11-year study incorporating 3595 rituximab-treated patients with rheumatoid arthritis (RA), 
143/3595 (4%) developed IgG below the reference range for at least 4 months [17]. Interestingly, in 
patients who developed low IgG, serious infection rates were higher than patients who never 
developed low IgG and higher than the all-exposure population, both before and after development 
of low IgG levels. The author surmised these patients might have an intrinsically higher infection 
inherent risk. 
 
Table 1: Summary table of studies in systematic literature review 
Study Design  Number 
of 
patients 
AIRD RTX dosage and other Other 
immunosuppression 
Immunoglobulin levels IGRT used 
No. of 
patients 
Roberts et 
al. 2015 [8] 
Retrospective 
study 
243 GPA/MPA/ 
EGPA/SLE/ 
Other 
Median 6g  Prior CYC 6g and 
glucocorticoids.  
Variable prior exposure 
to other DMARDs  
IgG mild 5-6.9 g/L, 
moderate 3-4.9 g/L and 
severe <3 g/L 
12 
Roberts et 
al. 2015 [14] 
Case series: 
subset from 
Roberts et al. 
2014  
12 GPA/MPA/ 
EGPA/SLE/ 
Other 
Median 6g  Prior CYC 6g and 
glucocorticoids. 
Variable prior exposure 
to other DMARDs 
IgG mild 5-6.9 g/L, 
moderate 3-4.9 g/L and 
severe <3 g/L 
12 (10/12 
SLE) 
 
Cortazar et 
al. 2017 [18] 
Retrospective 
evaluation 
229 AAV Induction therapy: combination therapy with RTX [2g], 
CYC, and high-dose steroids. 
Maintenance therapy: RTX with or without low-dose 
prednisone 
Significant 
hypogammaglobulinemia, 
IgG<4g/L. 
5 
(maintenanc
e group) 
Gottenberg 
et al. 2010 
[21] 
Cohort study  1303 RA 416 patients treated with 
RTX alone and 821 patients 
treated with RTX plus a 
nonbiologic 
DMARD. 
 
Prior anti-TNF and 
DMARDS. Pre-
medication 
corticosteroids in 1004 
patients.  
 
Hypogammaglobulinemia 
IgG<6 g/L 
- 
Makatsori et 
al. 2014 [32] 
Retrospective 
review Case 
series from 
audit of 114 
19 4 RA 
2 SLE 
13 other 
(haematological)  
Not specified Yes but not specified Hypogammaglobulinemia 
IgG≤4g/L. 
18 
Besada et al 
2014 [20] 
Cohort study 29 GPA Median cumulative dose 9g 
after RTX initiation.  
 
Prior CYC, concurrent 
prednisolone and other 
immunosuppression   
Hypogammaglobulinemia 
<6 g/L 
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Marco et al. 
2014 (7) 
Retrospective 
review  
177 Primary systemic 
vasculitis/ 
GPA/MPA/EGPA/
SLE/ Behcet’s 
disease/ HSP 
Median 5.9g CYC, MMF, HCQ, AZA, 
MTX, 5% other 
Mild (IgG 5–5.9 g/L), 
moderate (3–4.9 g/L) and 
severe (<3 g/L). 
6 
Venhoff et 
al. 2014 [22] 
Retrospective 
analysis 
37 GPA/MPA RTX induction regimens : 
2 infusions of 0.5 g each in 7 
patients and 1 g each in 
30 patients.  
 
 
RTX induction therapy, 
followed by 
maintenance with 
DMARDs.  Previous CYC 
in 92%.  
Hypogammaglobulinemia 
IgG<5g/L 
- 
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CYC = cyclophosphamide, RTX = rituximab, CTD =connective tissue disease RA= rheumatoid arthritis, GPA = Granulomatosis with Polyangiitis, MPA = microscopic 
polyangiitis, AAV= ANCA-associated vasculitis, EGPA = Eosinophilic Granulomatosis with Polyangiitis, SLE = systemic lupus erythematosus, HSP = Henoch-Schonlein 
purpura, TNF= tumor necrosis factor, DMARD = Disease-modifying anti-rheumatic drugs, AZA =azathioprine, MMF= mycophenolate mofetil, MTX = methotrexate, LEF = 
leflunomide, HCQ = hydroxychloroquine, SIE = serious infection events. 
 
3.2 Identification of risk factors for the development of numerical or symptomatic 
hypogammaglobulinemia  
The identification of patients at risk of hypogammaglobulinemia can help reduce associated infection-
related morbidity. A low IgG prior to rituximab treatment is a predictor of sustained 
hypogammaglobulinemia, highlighted in several 3 studies [8, 14, 18].  The other possible risk factors 
are cumulative cyclophosphamide dose prior to rituximab therapy and use of other 
immunosuppressive agents [7, 19,20]. 
 
Cortazar et al reported that baseline IgG level at the start of maintenance therapy for AAV was the 
only factor associated with subsequently developing ‘significant’ hypogammaglobulinemia, defined as 
IgG <4 g/L, during maintenance rituximab therapy (HR 0.25 per 0.5 g/L increase in IgG level [95% CI 
0.11, 0.56]; p= 0.001) [18]. Only patients with baseline maintenance IgG in the lowest quartile (4.08–
5.59 g/L) were noted to develop hypogammaglobulinemia. However, 82% of patients in the lowest 
baseline IgG quartile maintained IgG >4 g/L during continuous maintenance rituximab therapy. 
Neither time since initial AAV diagnosis, nor duration of B-cell depletion before onset of maintenance 
BCTT was associated with future hypogammaglobulinemia. The stability of IgG levels was independent 
of repeated rituximab doses. This was suggested to be due to a long-lived plasma cell population 
resistant to immunosuppressive agents and able to maintain the IgG pool. Increasing age [adjusted 
incident rate ratio {IRR}= 1.46 (95% CI 1.19, 1.78) p<0.001] and baseline maintenance IgG < 4 g/L 
[adjusted IRR= 2.13 (95% CI 1.04, 4.36) p= 0.04] were associated with developing a serious infection 
during maintenance therapy [18]. 
In granulomatosis with polyangiitis (GPA), the largest reduction in immunoglobulin levels occurred 
after remission induction with rituximab [20]. Subsequent maintenance therapy increased the risk of 
discontinuation due to hypogammaglobulinemia (HR 8.4, 95% CI 1.14 – 63, p= 0.037) [20]. Cumulative 
rituximab dose did not influence immunoglobulin levels, in contrast to cumulative cyclophosphamide 
[20]. Cumulative cyclophosphamide dose of 10g increased the risk of discontinuing rituximab due to 
hypogammaglobulinemia (HR 1.14 95% CI 1.01- 1.3 p= 0.034), suggesting a synergistic effect of 
cyclophosphamide and rituximab on B-cells in GPA patients [20]. Cyclophosphamide-associated 
hypogammaglobulinemia pre-rituximab may increase the risk of hypogammaglobulinemia during 
long-term maintenance. Of the variability in the IgG level during rituximab maintenance, 40% was 
reported to have been due to patient age, total cyclophosphamide cumulative dose (R2 = 0.107, p = 
0.047) or baseline IgG (R2 = 0.179, p = 0.013) [20]. Roberts et al noted a weak association between 
prior cyclophosphamide exposure and nadir IgG concentration (Spearman r = -0.1364, p = 0.035), but 
no association with cumulative rituximab dose [8].  
 
In another study of 177 patients with multisystem autoimmune disease treated with rituximab, 
baseline IgG levels were lower in patients who had received prior cyclophosphamide treatment (69% 
of patients) at the time of the first rituximab dose [(8.85 g/L vs. 10.4 g/L) (p = 0.025)], but not at 60 
months [(7.9 g/L vs. 9.7 g/L) (p=0.138) (N=51)]. No association between prior cyclophosphamide 
exposure and development of hypogammaglobulinemia during rituximab therapy was seen. Higher 
cumulative corticosteroid exposure during follow-up was associated with hypogammaglobulinemia. A 
reduction in severe infection rates over the study period was noted with minimisation of 
corticosteroids and avoidance of concomitant immunosuppression. There was no association 
between diagnosis and development of hypogammaglobulinemia (Chi-square = 3.24; df = 2; p = 0.198). 
The authors concluded that transient mild to mo
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hypogammaglobulinemia observed with repeat rituximab dosing were not dominant factors in 
infection risk, provided careful monitoring with judicious use of prophylactic therapies occurred [7].  
 
Results from Gottenberg et al showed that low IgG <6g/L before initiation of rituximab treatment (OR 
4.9 [95% CI 1.6–15.2], p = 0.005) was independently associated with higher risk of severe infection in 
the year following rituximab administration in RA patients. Six of 29 patients (20.7%) with low baseline 
IgG subsequently developed a severe infection, compared with 31/605 patients (5.1%) with normal 
baseline IgG [21].   
 
 
3.3 Monitoring for the development of hypogammaglobulinemia 
There are no specific biomarkers which are proven to guide rituximab treatment, though flow 
cytometry measurements of CD19+ B-cells are often performed [22]. Early recognition of 
hypogammaglobulinemia in BCTT-treated patients is important to prevent infection-associated 
morbidity. Cortazar et al concluded that immunoglobulin levels fall more rapidly during induction than 
in maintenance therapy. IgG levels declined at a mean rate of 6% per month (95% CI 4, 8%) during 
induction therapy [(52% per year when standardized to a common time unit (95% CI 39, 61%)]. During 
maintenance, IgG levels fell by a mean of 0.6% per year (95% CI -0.2, 1.4%) [18].  
 
In patients with multisystem autoimmune disease, Marco et al observed that following rituximab 
treatment, 61/177 patients (34%) had hypogammaglobulinemia for at least 3 consecutive months 
during follow-up (10% mild [IgG 5-5.9 g/L], 20% moderate [IgG 3-4.9] and 4% severe [IgG<3]). 
Excluding those with hypogammaglobulinemia at baseline, the median time to numerical 
hypogammaglobulinemia was 18 months (range 1–65 months) and it took 35 months to develop 
maximum severity hypogammaglobulinemia (range 1–70 months) [7].  
 
For AAV, current EULAR guidelines recommend testing serum immunoglobulin levels prior to each 
course of rituximab and in patients who develop recurrent infection [23]. Involvement of a clinical 
immunologist is recommended in patients who develop persistent hypogammaglobulinemia [23]. BSR 
guidelines for rituximab in RA recommend immunoglobulin levels should be checked prior to 
commencing therapy, 4–6 months after infusions and before re-treatment [24]. The AAAAI note the 
importance of checking baseline immune function in AIRD patients started on rituximab [25]. Checking 
baseline immunoglobulins may also assist in distinguishing drug-induced hypogammaglobulinemia 
from uncovering of undiagnosed PID such as common variable immunodeficiency [25]. 
 
 
3.4 Intervention thresholds for commencing IGRT  
The United Kingdom (UK) DoH guidelines recommend initiating IGRT in patients with secondary 
hypogammaglobulinemia of any cause (IgG < 5 g/L) provided there is demonstrable functional 
antibody deficiency1 and antibiotic prophylaxis for a period of 3 months is unsuccessful in preventing 
infections [26]. Currently there is no evidence base for the use of prophylactic antibiotics in drug-
induced secondary hypogammaglobulinemia. In this group of patients there are no controlled trials of 
antibiotic prophylaxis versus IGRT. There is an unresolved debate regarding the benefits of IGRT, when 
considered against its costs and risks, as opposed to long-term antibiotic prophylaxis, which is cheaper 
but with attendant risks of microbial resistance.  
                                                             
1 Functional antibody deficiency refers to failure of antibody response to polysaccharide antigens such as pneumococcus (measured as 
response to the unconjugated polysaccharide vaccine, rather than the conjugate vaccine) 
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In a case series of 12 patients (10 with vasculitis), the threshold for commencing IGRT was either 
moderate hypogammaglobulinemia (IgG<5g/L) or severe (<3 g/L), plus recurrent or persistent 
infections despite antimicrobial prophylaxis and functional antibody deficiency [14]. IGRT was initiated 
as per DoH guidelines and titrated dependent on infection rate and IgG levels [14]. A minimum trough 
IgG concentration of 8-10 g/L was used, similar to treatment guidelines for common variable 
immunodeficiency. An overall reduction in the frequency and severity of infections following 
commencement of IGRT was described [14].  
Cortazar et al noted during maintenance therapy with BCTT, median IgG level was 4.08 g/L at initiation 
of IGRT for the 5 patients requiring IGRT for recurrent infections [18]. Marco et al. reported IGRT was 
used in patients with infections despite antibiotic prophylaxis and moderate or severe 
hypogammaglobulinemia (IgG < 5 g/l) [7].  
Currently there is no agreement on a particular threshold level of IgG for intervention with IGRT in 
AIRD.    
 
3.5 Initiation and administration of IGRT 
Although there are no specific guidelines for the management of drug-induced 
hypogammaglobulinemia in AIRD, the principles of management are essentially the same as that for 
secondary antibody deficiency associated with B-cell lymphoproliferative disease.  
The decision to start IGRT should involve the patient, clinical immunologist and the patient’s 
autoimmune disease physician. DoH clinical guidelines for all causes of secondary antibody deficiency 
recommend immunoglobulin initially dosed at 0.4/kg/month [26].  The dose should be titrated to 
achieve an IgG trough level within the reference range, to achieve a significant reduction in the burden 
of bacterial infections. Evidence from IGRT in PID suggests that this approach is likely to optimise 
patient care [27]. Target trough IgG levels should be adjusted on an individual basis, and may be higher 
in patients with complications such as bronchiectasis [27]. Both intravenous and subcutaneous routes 
of administration should be considered [26]. 
Sustained hypogammaglobulinemia is reported to occur in a minority of patients after rituximab 
treatment, who may require long-term IGRT. In the largest study where data is available, 12/243 
(4.2%) patients with a range of AIRD required IGRT [14, 25]. In an AAV study, 7/55 (21%) patients 
treated with cyclophosphamide followed by rituximab required IGRT [19]. The decision to discontinue 
rituximab can be considered in patients with an IgG < 5 g/l, with a downward trajectory and recurrent 
infections [7].  This decision should be balanced against ongoing disease activity, the benefit derived 
from rituximab treatment and the availability of alternative therapeutic options [7]. 
 
3.6 Hypogammaglobulinemia with other immunosuppressive drugs  
There is no evidence to date of hypogammalobulinaemia as a clinical problem in patients treated with 
non-depleting B-cell medications such as belimumab or atacicept, but numbers of patients treated are 
much less than with rituximab [28, 29]. No significant difference was noted between belimumab and 
placebo in development of hypogammaglobulinemia [28]. While reductions in immunoglobulin levels 
were noted with atacicept, no cases of severe hypogammagloblinaemia (< 3g/L) were noted, and no 
increase in serious infections [29].   
 
Patients with AIRD have often had previous exposure to other medicines associated with 
hypogammaglobulinemia, including corticosteroids, cyclophosphamide (as discussed above), gold, 
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mycophenolate mofetil, alemtuzumab, sulfasalazine and ciclosporin [14]. These drugs may also 
confound the potential relationship between IgG levels and infection due to effects beyond the B-cell 
lineage [14].   
   
 
3.7 The potential role for memory B-cell monitoring 
 
B-cell repopulation following rituximab treatment in patients with AIRD has not been studied 
systematically over a long-term period. There is evidence to suggest a direct correlation between 
numbers of switched memory (CD27+ IgM- IgD-) B-cells and risk of disease relapse following rituximab 
treatment in AAV, but this data awaits confirmation [22]. Disease relapse reported in AAV is common 
following rituximab cessation, and it is often heralded by B-cell reconstitution [18].  Persistent loss of 
memory B-cells may be a clue to development and persistence of hypogammaglobulinemia [22]. 
 
 
3.8 Vaccination strategies and performance  
 
EULAR recommendations state that vaccination status should be assessed during the initial work-up 
of patients with AIRD. The decision to vaccinate patients should be decided on a case by case basis, 
following evaluation of the risks and benefits in the context of a patient’s immunocompetence [30].  
EULAR recommend avoiding live attenuated vaccines in immunosuppressed patients with AIRD when 
possible. Ideally all indicated non-live vaccinations should be administered at least 4 weeks prior to 
the initiation of BCTT therapy [31]. However this should not delay BCTT in urgent cases. In particular 
vaccination against influenza, pneumococcus, tetanus toxoid every 10 years and hepatitis B for at-risk 
populations should be considered [31]. Patients receiving conventional immunosuppressive therapy 
or undergoing BCTT may have impaired response to vaccination with pneumococcal polysaccharide 
or novel antigens [18]; testing vaccination responses may be indicated [32]. B-cell recovery may 
provide a marker to guide revaccination schedules [33]. Influenza and pneumococcal vaccinations are 
recommended as there is a high level of respiratory tract infections in rituximab treated patients.  
Test vaccinations currently are recommended by DoH to evaluate for functional antibody deficiency 
in secondary hypogammaglobulinemia (utilising polysaccharide vaccines such as unconjugated 
pneumococcus). However, as there is substantial data showing rituximab impairs protective humoral 
responses, this may be superfluous in some cases, particularly if there is severe 
hypogammaglobulinemia. EULAR reported from a systematic review that humoral responses to 
pneumococcal vaccine were impaired for 28 weeks after treatment with rituximab, and to influenza 
vaccine for 1-3 months after rituximab [30].  
 
3.9 Health economics 
There is limited data regarding health economics of IGRT for secondary hypogammaglobulinemia. 
Further evaluation in the UK is required. There is more experience and established data for the health 
economics for IGRT in PID and in some haematological malignancies. There is data on health costs in 
AAV where hospitalisation more than doubles the annual health costs per patient, to over $80,000 
(2013 US prices) [34]. 
 
4. Discussion  
In this review, we have assessed the role of IGRT in the management of BCTT-induced secondary 
hypogammaglobulinemia in AIRD. At present there are few studies focused on BCTT and these are 
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mostly retrospective cohort studies. The main limitations are the small numbers of such patients 
receiving IGRT in these studies, and the lack of randomised controlled trials.  
The evidence supports pre-existing low IgG levels being a risk factor for developing 
hypogammaglobulinemia during BCTT, however this should not be a contra-indication to commencing 
or continuing BCTT. It has not been definitively established that patients with previous 
cyclophosphamide or other immunosuppressive drug exposure are at a higher risk of developing 
hypogammaglobulinemia. Independent of the effect of non-rituximab disease treatment, different 
diseases appear to vary in their susceptibility to low IgG levels after rituximab. The most common 
diagnosis was AAV in patients receiving IGRT subsequent to BCTT. The explanation for this variability 
is not yet known.  It is recommended that all patients should have serum immunoglobulin 
measurements prior to commencing BCTT, to establish a baseline and exclude underlying 
immunodeficiency. These levels should be monitored for long-term changes during follow-up [32].  
 
We consider numerical hypogammaglobulinemia as a low IgG level below the local laboratory 
reference range. Patients with numerical hypogammaglobulinemia may not be symptomatic and 
therefore may not require IGRT. Agreement regarding definitions of mild, moderate and severe 
hypogammaglobulinemia is lacking. Evidence is limited for clear intervention thresholds for IGRT, such 
as asymptomatic patients with numerical hypogammaglobulinemia.  
Currently there is no standardised definition for recurrent infection. However, infections characteristic 
of hypogammaglobulinemia are typically sino-pulmonary, caused by encapsulated organisms such as 
pneumococcus [35]. The decision to start IGRT should consider a history of serious, persistent, unusual 
or recurrent (SPUR) infections. IGRT should be considered in patients with a significant burden of 
infections accompanied by hypogammaglobulinemia [36]. The role of measurement of baseline 
specific antibodies and responses to test vaccinations has not been universally agreed upon.  
Treatment targets for IGRT would be valuable, as the current evidence is unclear and is largely based 
on evidence from PID. Guidelines on when to refer a patient to Clinical Immunology during BCTT are 
needed, especially for complex cases. For example, if a patient is symptomatic without 
hypogammaglobulinemia or where a patient is asymptomatic but has numerical 
hypogammaglobulinemia, would referral be indicated by the autoimmune disease physician? 
Health economic data for secondary hypogammaglobulinemia in AIRD and patient assessment tools 
would aid the evaluation of current IGRT practice and improve quality of life outcomes.  While BCTT 
for AIRD can be efficacious, the risk of hypogammaglobulinemia and infections (particularly when 
pursuing prolonged maintenance therapy) needs balancing against the risk of disease relapse if BCTT 
is discontinued. In this context IGRT has an important role in the management of (symptomatic) 
hypogammaglobulinemia [14]. 
We recognise the limitations of this SLR, due to the sparse data available on the use of IGRT for BCTT 
associated hypogammaglobulinemia in AIRD. Long-term outcome data and randomised controlled 
studies from this group of patients are not present in the current literature. 
 
5. Research Agenda 
 
The effect of IGRT in reducing infection frequency and prevention of hospital admissions has been 
demonstrated in small studies in SID. IGRT initiation appeared to be associated with a reduction in the 
number of infections in moderate or severe hypogammaglobulinemia in a case series of AAV [14] and 
in mixed study populations of Haematology and Rheumatology patients [30]. Further research in 
larger prospective studies is required in AIRD.  
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BCTT use is likely to increase in AIRD, with a wider range of B-cell agents (including biosimilars). The 
findings from this review have highlighted areas in need of further research. At present data from PID 
and haematological malignancies provides guidance, whilst awaiting further studies in AIRD. Research 
regarding immunoglobulin recovery following BCTT, the safety of continuing BCTT in patients with low 
or falling IgG, use of memory B-cell panels for monitoring hypogammaglobulinemia development, and 
long-term prognosis of AIRD patients with hypogammaglobulinemia are needed [8]. Studies of IGRT 
efficacy and cost-effectiveness in this group of patients are warranted.  
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